Zika Vaccines Are Widely Being Developed In Many Research Institute to Combat the Increasing Prevalence of the Virus
Zika Vaccines |
Vaccination
against Zika is the first step toward preventing or controlling the disease. It
is important to receive the vaccine during all stages of exposure, including
the early postnatal period. Zika vaccines help protect against intrauterine
infection and reduce the risk of transmission to the unborn child. It is
important to note that the African Zika virus is not associated with congenital
malformations.
According
to Coherent Market Insights the Zika
Vaccines Market Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2022-2028.
As the
Zika virus continues to spread throughout the Americas, research into new Zika vaccines
is advancing. In September, a phase 1 clinical trial of the DNA vaccine was
started in Texas. A phase 2b study will be conducted in multiple sites where
ZIKV is endemic. These studies will provide more evidence of the effectiveness
of the vaccine in protecting against the disease. In the meantime, there is no
known cure for Zika.
Furthermore,
human antibodies to ZIKV have been developed in laboratories. Human B-cell
immortalization was used to identify the most effective antibodies to block
ZIKV infection. The ZIKV-117 mAb was identified as broadly neutralizing and
inhibited ZIKV infection in vitro. It recognizes a unique quaternary epitope in
the E protein dimer-dimer interface. There is also a bispecific mAb being
developed that addresses concerns of antiviral resistance.
A vaccine
that protects against Zika is not far away. Researchers are closely monitoring
the development of a Zika vaccines to combat the outbreak and are developing an
experimental weakened version. However, there are several challenges in
developing this vaccine. Despite its potential benefits, the costs and
technical challenges may outweigh the benefits. However, there is little doubt
that a vaccine can help prevent the disease, which could be fatal in some
cases. Recently in January 2022, researchers at Trudeau Institute, Texas
Biomedical Research Institute, SNPRC and WRAIR created a Zika vaccine candidate
that was found to be effective at preventing the virus passing from mother to
fetus in preclinical animal studies.
Comments
Post a Comment